{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"}],"units":"Participants"}],"description":"Number of participants with at least one positive titer treatment emergent antibody positive neutralizing antibody detecting. A sample will be considered positive for anti-Ramucirumab antibodies if it exhibits a post-baseline antibody level exceeding the normal anti-Ramucirumab antibody level seen in healthy untreated individuals.","groups":[{"description":"Cycles repeat every 3 weeks until disease Progression, unacceptable toxicity, or withdrawal.\n\nDocetaxel: Docetaxel: 75 mg/m2 on Day 1 of each 21-day cycle\n\nRamucirumab DP: Ramucirumab (DP): 10 mg/kg IV on day 1 of each 21-day cycle","id":"OG000","title":"Docetaxel + Ramucirumab DP"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All randomized participants who received at least one dose of study drug and had baseline and post baseline anti-ramucirumab antibodies.","reportingStatus":"POSTED","timeFrame":"Cycle 1:Predose,EOI,1hr,48hr,72hr,168hr,336 hr post-EOI:Cycle 2:Predose,1hr post-EOI;Cycle 3:Predose,1hr,48hr,72hr,168hr,336hr post-EOI;Cycle 4:Predose,1hr post-EOI;Cycle 6:Predose,1hr post-EOI","title":"Number of Participants With Serum Anti-Ramucirumab Antibody Assessment","type":"SECONDARY","unitOfMeasure":"Participants"}